Assuntos
Cardiomiopatias/diagnóstico por imagem , Cardiopatias Congênitas/diagnóstico por imagem , Insuficiência Cardíaca/diagnóstico por imagem , Ventrículos do Coração/diagnóstico por imagem , Adolescente , Cardiomiopatias/complicações , Feminino , Cardiopatias Congênitas/complicações , Insuficiência Cardíaca/etiologia , Humanos , Imageamento por Ressonância MagnéticaRESUMO
BACKGROUND: To develop a Chinese version of the National Eye Institute Visual Function Questionnaire (CHI-VFQ-25) and to test its reliability and validity in a group of patients with eye diseases in Hong Kong. METHODS: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was translated into Chinese. Patients were recruited from Hong Kong, and their demographic data and visual acuity were documented. Psychometric properties of the CHI-VFQ-25, including internal consistency, test-retest reliability, item-scale correlations and construct validity were tested. RESULTS: 250 patients were recruited. The mean age of the patients was 66.04 (SD 14.00). 46% of them were male. The non-response rate and the floor and ceiling numbers of the CHI-VFQ-25 were calculated. The internal consistency was high in most subscales (except the general health and driving subscales), with Cronbach alpha ranging from 0.72-0.90. The test-retest reliability was excellent (intraclass correlation coefficient >0.90). Patients with worse visual acuity had significantly lower scores on the CHI-VFQ-25 supporting construct validity. CONCLUSION: The CHI-VFQ-25 is a reliable and valid tool for assessing the visual functions of Chinese patients with eye diseases in Hong Kong. Some questions had high non-response rates and should be substituted by the available alternatives.
Assuntos
Oftalmopatias/diagnóstico , Inquéritos e Questionários , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Hong Kong , Humanos , Idioma , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Reprodutibilidade dos Testes , Adulto JovemRESUMO
Our increasing understanding of the regulatory mechanisms involved in the pathogenesis of disease is opening up opportunities for therapeutic intervention. To tackle the unmet disease burden, the last decade has seen the emergence of gene-targeting small-molecule nucleic acid-based strategies, such as antisense oligodeoxynucleotides, ribozymes, small interfering RNA and DNAzymes. DNAzymes represent promising candidates for drug therapy in a wide range of diseases, such as cancer and cardiovascular disorders. This brief review will discuss recent developments in DNAzymes and their therapeutic potential.